Stryker (SYK) Stock
NASDAQ · SYK
275.29
Fundamentals
Market cap
$104.47B
Price / Earnings ratio
27.7x
Price / Sales ratio
4.0x
Price / Book ratio
4.3x
Return on assets
7.0%
Ex-Dividend date
30 Jun 2026
Last payment date
31 Jul 2026
Dividend amount
$0.88
Dividend yield
1.28%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?
NeutralSYKSeptember 23, 2026
Zacks Investment ResearchNeutral
Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?
SYK

Zacks Investment Research
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
NeutralSYKSeptember 23, 2026
Zacks Investment ResearchNeutral
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
SYK

Zacks Investment Research
Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEX
NeutralSYKSeptember 17, 2026
Zacks Investment ResearchNeutral
Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEX
SYK

Zacks Investment Research
GEHC or SYK: Which Is the Better Value Stock Right Now?
NeutralSYKSeptember 16, 2026
Zacks Investment ResearchNeutral
GEHC or SYK: Which Is the Better Value Stock Right Now?
SYK
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral3
Buy10
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2025
30B20B10B0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2025
57B38B19B0
Revenue to Profit
2025$25.1B
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$3.2B
Net incomeEarnings
EPS forecast
Actual EPS
$3.13
$3.07
Q2FY25
$3.19
$3.14
Q3FY25
$4.39
Q4FY25
$3.03
Q1FY26
$3.49
Q2FY26
The market is expecting earnings per share of $3.49 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?
NeutralSYKSeptember 23, 2026
Zacks Investment ResearchNeutral
Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?
SYK

Zacks Investment Research
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
NeutralSYKSeptember 23, 2026
Zacks Investment ResearchNeutral
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
SYK

Zacks Investment Research
Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEX
NeutralSYKSeptember 17, 2026
Zacks Investment ResearchNeutral
Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEX
SYK

Zacks Investment Research
GEHC or SYK: Which Is the Better Value Stock Right Now?
NeutralSYKSeptember 16, 2026
Zacks Investment ResearchNeutral
GEHC or SYK: Which Is the Better Value Stock Right Now?
SYK

Business Wire
Securities Fraud Investigation Into Stryker Corporation (SYK) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
NeutralSYKSeptember 10, 2026
Business WireNeutral
Securities Fraud Investigation Into Stryker Corporation (SYK) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
SYK

Business Wire
Stryker Corporation (SYK) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
NeutralSYKSeptember 10, 2026
Business WireNeutral
Stryker Corporation (SYK) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
SYK

Business Wire
Securities Fraud Investigation Into Stryker Corporation (SYK) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
NeutralSYKSeptember 9, 2026
Business WireNeutral
Securities Fraud Investigation Into Stryker Corporation (SYK) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
SYK

24/7 Wall Street
Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money
NeutralSYKSeptember 4, 2026
24/7 Wall StreetNeutral
Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money
SYK

Zacks Investment Research
Stryker Launches FDA-Cleared Apple Vision Pro Surgical App
NeutralSYKSeptember 3, 2026
Zacks Investment ResearchNeutral
Stryker Launches FDA-Cleared Apple Vision Pro Surgical App
SYK

Zacks Investment Research
Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio
NeutralSYKSeptember 1, 2026
Zacks Investment ResearchNeutral
Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio
SYK
About Stryker
Stryker is one of the world’s leading medical technology companies and, together with our customers, is driven to make healthcare better. We offer innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes.
SectorHealthcare
IndustryMedical Devices
Employees56,000
CEOMr. Kevin A. Lobo
IPO DateFeb 1, 1988
HeadquartersPortage, MI
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Kevin A. Lobo | Chairman & CEO | 1965 |
| Mr. Spencer S. Stiles | President & COO | 1977 |
| Mr. Preston W. Wells | VP & CFO | 1977 |
| Mr. Viju S. Menon | Group President of Global Quality & Operations | 1968 |
| Mr. J. Andrew Pierce | Group President of MedSurg & Neurotechnology | 1974 |
| Mr. William E. Berry Jr. | VP & Chief Accounting Officer | 1966 |
| Mr. Robert C. Cohen | CTO and VP of Global R&D - Joint Replacement | — |
| Ms. Debra S. King | VP and Chief Digital & Information Officer | 1972 |
| Mr. Nick Mead | Vice President of Investor Relations | — |
| Mr. Robert S. Fletcher | VP & Chief Legal Officer | 1971 |
Fundamentals
Valuation
Market cap$104.47B
Price-to-sales ratio4.00
Price-to-book value4.31
Price-earnings ratio27.70
Return on Equity15.00%
Return on Sales22.00%
Return on Assets7.00%
PEG ratio1.29
Earnings Per Share
Earnings Per Share$9.74
Income Statement
Average volume2,987,521
EBITDA$5.99B
1 year high (52w)$392.55
1 year low (52w)$267.00
Dividend
Ex dividend date30 Jun 2026
Dividend amount$0.88
Dividend yield1.28%
Last payment date31 Jul 2026
Dividend yield (TTM)1.26%
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
13 Wall Street Analyst Ratings
BUY
77% Buy
23% Hold
0% Sell
Target price
$366.58
Est return
34.57%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.6 | -0.8 | -11.8 | +11.8 | ||||||||
| 2022 | -7.6 | +5.9 | +1.8 | -10.3 | -1.0 | -12.7 | +5.3 | -3.9 | -2.0 | +9.2 | +6.3 | +1.5 |
| 2023 | +3.2 | -5.8 | +9.8 | +4.2 | -8.1 | +9.5 | -4.9 | +1.5 | -3.9 | -1.3 | +8.9 | +0.6 |
| 2024 | +13.2 | +2.5 | +1.3 | -5.1 | +4.0 | +0.3 | -2.7 | +8.2 | +0.5 | -0.3 | +6.8 | -7.6 |
| 2025 | +9.1 | -1.3 | -5.7 | +0.2 | +2.3 | +3.9 | -1.0 | +3.6 | -5.2 | -2.2 | +3.6 | -5.6 |
| 2026 | +6.1 | +5.2 | -15.1 | -4.3 | +3.5 | +5.1 | +3.9 | -5.1 | -14.2 |
Corporate actions
Upcoming
DividendQ3/26
Ex-dividend date30 Sep 2026
Payable date30 Oct 2026
Amount per share$0.88
Past
DividendQ2/26
Ex-dividend date30 Jun 2026
Payable date31 Jul 2026
Amount per share$0.88
DividendQ1/26
Ex-dividend date31 Mar 2026
Payable date30 Apr 2026
Amount per share$0.88
DividendQ4/25
Ex-dividend date31 Dec 2025
Payable date30 Jan 2026
Amount per share$0.88
DividendQ3/25
Ex-dividend date30 Sep 2025
Payable date31 Oct 2025
Amount per share$0.84
DividendQ2/25
Ex-dividend date30 Jun 2025
Payable date31 Jul 2025
Amount per share$0.84
DividendQ1/25
Ex-dividend date31 Mar 2025
Payable date30 Apr 2025
Amount per share$0.84
DividendQ4/24
Ex-dividend date31 Dec 2024
Payable date31 Jan 2025
Amount per share$0.84
DividendQ3/24
Ex-dividend date30 Sep 2024
Payable date31 Oct 2024
Amount per share$0.80
DividendQ2/24
Ex-dividend date28 Jun 2024
Payable date31 Jul 2024
Amount per share$0.80
DividendQ1/24
Ex-dividend date27 Mar 2024
Payable date30 Apr 2024
Amount per share$0.80
DividendQ4/23
Ex-dividend date28 Dec 2023
Payable date31 Jan 2024
Amount per share$0.80
DividendQ3/23
Ex-dividend date28 Sep 2023
Payable date31 Oct 2023
Amount per share$0.75
DividendQ2/23
Ex-dividend date29 Jun 2023
Payable date31 Jul 2023
Amount per share$0.75
DividendQ1/23
Ex-dividend date30 Mar 2023
Payable date28 Apr 2023
Amount per share$0.75
DividendQ4/22
Ex-dividend date29 Dec 2022
Payable date31 Jan 2023
Amount per share$0.75
DividendQ3/22
Ex-dividend date29 Sep 2022
Payable date31 Oct 2022
Amount per share$0.70
DividendQ2/22
Ex-dividend date29 Jun 2022
Payable date29 Jul 2022
Amount per share$0.70
DividendQ1/22
Ex-dividend date30 Mar 2022
Payable date29 Apr 2022
Amount per share$0.70
DividendQ4/21
Ex-dividend date30 Dec 2021
Payable date31 Jan 2022
Amount per share$0.70
DividendQ3/21
Ex-dividend date29 Sep 2021
Payable date29 Oct 2021
Amount per share$0.63



